Highlights from the Week of 6th April 2026 - 13th April 2026

VYUHPHARMA

(Launch)

Ascendis Pharma launches the once-weekly YUVIWEL in the US for achondroplasia with open epiphyses to provide continuous systemic exposure to CNP

(EU, Approval)

EC grants approval to Sanofi and Regeneron's DUPIXENT, a IL4 and ILI3 signal inhibitor to treat moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years

(MHRA, Approval)

MHRA accepts Savara's MOLBREEVI application for marketing authorization indicated to treat autoimmune pulmonary alveolar proteinosis

(FDA, Fast Track)

Climb Bio obtains FDA Fast Track Designation for budoprutug, an anti-CD19 monoclonal antibody, for the treatment of primary membranous nephropathy

VYUHPHARMA

(Collaboration)

Gan & Lee Pharmaceuticals enters into a license agreement with JW Pharmaceutical to collaborate on the clinical development, regulatory filing and commercialization of Bofanglutide Injection in South Korea

(Collaboration)

Oxford Biotherapeutics collaborates with Bristol Myers Squibb, leveraging its OGAP-Verify target discovery and validation platform to generate next-generation T-cell engager molecules

(Phase 3, Results)

Aurobindo Pharma's subsidiary, CuraTeQ reports positive Phase 3 results for BPII, a XOLAIR biosimilar that showed equivalence, meeting secondary endpoints including relative potency and dose response

(Phase 3, Results)

Amgen's Phase 3 TEPEZZA OBI trial for moderate-to-severe TED met all primary and secondary endpoints, achieving a 77% proptosis reduction versus placebo over 24 weeks